Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 13 Rectal Neoplasms 4 Neoplasm Metastasis 2 Colonic Neoplasms 2 Carcinoma, Hepatocellular 2 Advanced Solid Tumors 2 Stomach Neoplasms 1 Solid Tumor Cancer 1 Sarcoma, Ewing 1 Sarcoma 1 Prostatic Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Neoplasms 1 Microsatellite-stable Colorectal Cancer 1 Metastatic Gastric Adenocarcinoma 1 Lung Neoplasms 1 HER2 IHC3+ Advanced Colorectal Cancer 1 Endometrial Neoplasms 1 Desmoid Tumors 1 Craniopharyngioma 1 Colorectal Cancer Metastatic 1 Breast Neoplasms 1 Anal Cancer Metastatic 1 Advanced Microsatellite Stable Colorectal Cancer 1 Adenomatous Polyposis Coli 1

Interventions

Fulvestrant 65 Letrozole 55 Paclitaxel 54 pembrolizumab 42 Trastuzumab 42 ribociclib 39 Specimen Handling 36 palbociclib 35 Capecitabine 35 Carboplatin 34 Anastrozole 34 Tamoxifen 32 exemestane 31 abemaciclib 31 pertuzumab 29 Cyclophosphamide 27 Magnetic Resonance Spectroscopy 26 trastuzumab deruxtecan 24 Radiotherapy 22 Surveys and Questionnaires 20 Blood Specimen Collection 20 olaparib 18 Biopsy 18 Standard of Care 17 Docetaxel 17 Taxes 15 130-nm albumin-bound paclitaxel 15 eribulin 14 Methods 14 Mastectomy, Segmental 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms × trifluridine tipiracil drug combination × 90 days × Clear all

NCT04489173 2026-05-22

TIBET

Borstkanker Onderzoek Groep

Phase 2 Completed

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡